Published in Hepatitis Weekly, December 22nd, 2003
The patent covers a family of synthetic oligonucleotides that contain CpG motifs. Cancer treatment applications protected by this patent include CpG TLR9 agonist monotherapy and combination therapies where CpG TLR9 agonists are used to enhance the anticancer activity of other regimens,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.